Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma
- PMID: 22156613
- DOI: 10.1158/1078-0432.CCR-11-2479
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma
Abstract
Purpose: To evaluate the effects of treatment with the potent mutant BRAF inhibitors GSK2118436 or vemurafenib (PLX4720) on immune responses to metastatic melanoma in tissues taken before and after treatment.
Experimental design: Thirty-seven tumor biopsies were collected from 15 patients with unresectable American Joint Committee on Cancer stage III or IV melanoma immediately before and approximately 7 days after the commencement of BRAF inhibitor treatment and at the time of tumor progression. Immunohistochemical staining was carried out on the biopsies using specific antibodies for CD8, CD4, CD20, CD1a, and Granzyme B.
Results: Tumor infiltration by CD4(+) and CD8(+) lymphocytes increased markedly following BRAF inhibitor treatment (both ρ = 0.015). There was a correlation between the degree of tumor infiltration by CD8(+) and Granzyme B-expressing lymphocytes in post-BRAF inhibitor-treated biopsies (r = 0.690 and ρ = 0.013). Increased intratumoral CD8(+) lymphocyte expression was correlated with a reduction in tumor size and an increase in necrosis in posttreatment biopsies (r = -0.793, ρ = 0.011; and r = 0.761, ρ = 0.004, respectively).
Conclusions: The increase in tumor-infiltrating lymphocytes induced by treatment with BRAF inhibitors provides strong support for conducting trials that combine BRAF inhibitors with immunotherapy in the hope of prolonging clinical responses.
Comment in
-
Rehabilitation for oncogene addiction: role of immunity in cellular sobriety.Clin Cancer Res. 2012 Mar 1;18(5):1192-4. doi: 10.1158/1078-0432.CCR-11-3322. Epub 2012 Jan 20. Clin Cancer Res. 2012. PMID: 22266272
Similar articles
-
PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.Clin Cancer Res. 2015 Jul 15;21(14):3140-8. doi: 10.1158/1078-0432.CCR-14-2023. Epub 2015 Jan 21. Clin Cancer Res. 2015. PMID: 25609064
-
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency.Clin Cancer Res. 2012 Apr 15;18(8):2326-35. doi: 10.1158/1078-0432.CCR-11-2515. Epub 2012 Feb 21. Clin Cancer Res. 2012. PMID: 22355009 Clinical Trial.
-
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.Clin Cancer Res. 2013 Jan 15;19(2):393-403. doi: 10.1158/1078-0432.CCR-12-1626. Epub 2012 Nov 30. Clin Cancer Res. 2013. PMID: 23204132 Free PMC article.
-
Vemurafenib for the treatment of BRAF mutant metastatic melanoma.Future Oncol. 2015;11(4):579-89. doi: 10.2217/fon.14.252. Future Oncol. 2015. PMID: 25686114 Review.
-
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.Oncotarget. 2014 Nov 15;5(21):10206-21. doi: 10.18632/oncotarget.2602. Oncotarget. 2014. PMID: 25344914 Free PMC article. Review.
Cited by
-
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response.Nat Rev Clin Oncol. 2024 Sep 24. doi: 10.1038/s41571-024-00943-6. Online ahead of print. Nat Rev Clin Oncol. 2024. PMID: 39317818 Review.
-
Desmoplastic small round cell tumor: from genomics to targets, potential paths to future therapeutics.Front Cell Dev Biol. 2024 Jul 30;12:1442488. doi: 10.3389/fcell.2024.1442488. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39139449 Free PMC article. Review.
-
Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.Nat Med. 2024 Sep;30(9):2540-2548. doi: 10.1038/s41591-024-03077-5. Epub 2024 Jun 21. Nat Med. 2024. PMID: 38907159 Free PMC article. Clinical Trial.
-
BRAFV600E Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist.Adv Ther. 2024 Jul;41(7):2576-2585. doi: 10.1007/s12325-024-02883-0. Epub 2024 May 28. Adv Ther. 2024. PMID: 38806993 Free PMC article.
-
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers.J Immunother Cancer. 2024 May 15;12(5):e008659. doi: 10.1136/jitc-2023-008659. J Immunother Cancer. 2024. PMID: 38754916 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials